NanoViricides, Inc. (NYSE American: NNVC) announced continued progress advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial evaluating its oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company said its proposed clinical trial has been approved by the DRC Pillar Committee, with preparations underway for ethics and regulatory submissions. NanoViricides noted that NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies can be difficult to deploy.
The company also highlighted the continued expansion of the outbreak, citing 1,561 confirmed cases and 506 deaths in the DRC as of July 6, while emphasizing that no approved treatment or vaccine currently exists for the Bundibugyo strain. NanoViricides said it believes NV-387’s broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains and noted that the same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product already shipped to the country for that study.
The significance of this announcement lies in the urgent need for effective treatments against the Bundibugyo ebolavirus, which has caused a severe outbreak with high mortality. The DRC outbreak underscores the limitations of current response capabilities, as existing therapies and vaccines are largely strain-specific. NV-387's broad-spectrum mechanism could offer a critical tool for outbreak control, especially in settings where intravenous therapies are impractical.
NanoViricides' oral gummies formulation represents a potential game-changer for outbreak management. Oral administration eliminates the need for cold chain storage and trained medical personnel for infusion, making it more deployable in remote areas. This could significantly improve treatment access and reduce mortality in future outbreaks.
The company's progress with regulatory approval in the DRC for the Mpox trial also suggests a streamlined pathway for Ebola. The dual development for Mpox and Ebola highlights the versatility of NV-387, which could be stockpiled for multiple viral threats. However, the company acknowledges the typical risks of drug development, including the need for substantial capital and no guarantee of clinical success.
For more information, visit the company's newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/LaNwF.
